• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck

    4/30/26 1:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email

    Solventum's Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value

    Outlines Three Initiatives to Improve Performance and Drive Value Creation at Solventum

    NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns nearly 5% of Solventum Corporation's common stock (NYSE:SOLV) ("Solventum" or the "Company") and is one of the Company's largest active shareholders, today published an open letter to the Solventum Board of Directors (the "Board") and an accompanying slide deck arguing that the Company continues to be significantly under-managed following its spin-out from 3M – and outlining three immediately actionable initiatives to restore performance and prioritize shareholder value creation.

    Trian believes Solventum's spin-out has been managed in a way that has maximized executive compensation, not shareholder value. When Solventum separated from 3M, management took one of the biggest performance resets of any U.S. spin-off in the last decade, erasing $13 billion in shareholder value relative to the $25 billion market capitalization analysts had projected at spin. The CEO has since been paid more than $80 million in just over two years – all in the context of a company with just a $12 billion market capitalization that has not delivered any return for shareholders.

    Despite Trian's efforts to engage constructively with the Board, Solventum has so far not taken action to drive shareholder value creation or add independent shareholder representation to the Board. Trian has heard from several large shareholders over recent weeks who have expressed their frustration with where the Company is today.

    Trian believes Solventum would be a considerably more valuable company today if the Board and management are willing to take steps to realize its potential, including:

    1. Right-sizing overhead costs, driving net productivity and reinvesting in growth in order to reach (and exceed) performance levels Solventum delivered inside of 3M
    2. Simplifying its portfolio and divesting non-core businesses, starting with the immediate separation of the Health Information Systems ("HIS") business
    3. Improving capital allocation by prioritizing share repurchases at current levels



    Trian's full letter and accompanying slides are available to view online at: https://trianpartners.com/wp-content/uploads/2026/04/Trian-Calls-on-Solventums-Board-to-Create-Value_-Publishes-Open-Letter-and-Slide-Deck-Combined-Wrap-Letter-Slides.pdf 

    About Trian Fund Management

    Founded in 2005, Trian is a multi-billion dollar investment management firm. Trian is a highly engaged shareholder, bringing an entrepreneurial spirit, deep operational expertise, and an ownership mentality to its public and private investments. Leveraging the 50+ years' operating experience of our Founding Partners, Nelson Peltz and Peter May, Trian seeks to invest in high quality companies with untapped potential. Trian works with management teams and boards to help companies execute operational and strategic initiatives designed to drive long-term shareholder value. For more: www.trianpartners.com

    Media Contacts:

    Anne A. Tarbell

    (212) 451-3030

    atarbell@trianpartners.com

    Paul Caminiti / Jacqueline Zuhse / Erin Craig

    Reevemark

    (212) 433-4600

    Trian@reevemark.com

    Investor Contact:

    Matt Underhill

    (212) 451-3171

    munderhill@trianpartners.com

    Disclaimer

    Except as otherwise set forth in this press release or the accompanying letter and presentation, the views expressed reflect the opinions of Trian Fund Management, L.P. and its affiliates ("Trian"), and are based on publicly available information with respect to Solventum Corporation (the "Company"). Please see the disclaimers in the accompanying presentation for important information regarding Trian's analyses and views. Trian recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with Trian's conclusions. Trian reserves the right to change any of its opinions expressed herein at any time as it deems appropriate and disclaims any obligation to notify the market or any other party of any such change, except as required by law. Trian disclaims any obligation to update the information or opinions contained in this press release or the accompanying letter and presentation. For the avoidance of doubt, this press release, letter, and presentation is not affiliated with or endorsed by the Company.

    This press release, accompanying letter and presentation are provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. This press release, accompanying letter and presentation do not constitute a solicitation of proxies and are not being made in connection with any proxy contest or director nomination. Funds managed by Trian currently beneficially own nearly 5% of the outstanding shares of the Company. These funds are in the business of trading – buying and selling– securities and intend to continue trading in the securities of the Company. You should assume such funds may from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise (including via short sales), buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.

    Some of the materials in this press release, accompanying letter and presentation, contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Trian.

    Certain financial projections and statements made herein have been derived or obtained from filings made with the Securities and Exchange Commission ("SEC") or other regulatory authorities and from other third-party reports. Trian shall not be responsible or have any liability for any misinformation contained in any third-party, SEC or other regulatory filing or third-party report.

    There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. The estimates, projections and potential impact of the opportunities identified by Trian herein are based on assumptions that Trian believes to be reasonable as of the date of this press release, letter, and presentation, but there can be no assurance or guarantee (i) that any of the proposed actions set forth in this information will be completed, (ii) that the actual results or performance of the Company will not differ, and such differences may be material, or (iii) that any of the assumptions provided in this press release and accompanying letter and presentation are accurate. Neither the press release nor the accompanying letter and presentation recommend the purchase or sale of any security.



    Primary Logo

    Get the next $SOLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    5/15/2026$94.00Outperform
    Wedbush
    5/14/2026$50.00Buy → Neutral
    UBS
    3/24/2026$60.00Sell
    Rothschild & Co Redburn
    1/26/2026$97.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/20/2026$100.00Neutral → Outperform
    Mizuho
    12/2/2025$100.00Neutral → Buy
    BTIG Research
    10/1/2025$77.00Neutral
    UBS
    9/11/2025$80.00Hold
    Jefferies
    More analyst ratings

    $SOLV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wendell Amy Mcbride bought $100,344 worth of shares (1,475 units at $68.03), increasing direct ownership by 41% to 5,039 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    3/11/26 6:31:11 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    SEC Filings

    View All

    SEC Form SD filed by Solventum Corporation

    SD - Solventum Corp (0001964738) (Filer)

    5/29/26 4:14:39 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    5/27/26 4:23:24 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Solventum Corp (0001964738) (Filer)

    5/20/26 4:14:28 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum to Participate in the 2026 Jefferies Healthcare Conference

    EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026, beginning at approximately 9:55 a.m. EDT in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pion

    5/27/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Participate in the 2026 BofA Securities Health Care Conference

    ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May 13, 2026, beginning at approximately 10:00 a.m. PDT in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challeng

    5/7/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports First Quarter 2026 Financial Results

    Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating

    5/5/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Solventum with a new price target

    Wedbush initiated coverage of Solventum with a rating of Outperform and set a new price target of $94.00

    5/15/26 8:30:16 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum downgraded by UBS with a new price target

    UBS downgraded Solventum from Buy to Neutral and set a new price target of $50.00

    5/14/26 8:07:23 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on Solventum with a new price target

    Rothschild & Co Redburn initiated coverage of Solventum with a rating of Sell and set a new price target of $60.00

    3/24/26 8:51:05 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Alban Carlos

    4 - Solventum Corp (0001964738) (Issuer)

    5/18/26 5:39:57 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Cox Carrie Smith

    4 - Solventum Corp (0001964738) (Issuer)

    5/18/26 5:39:18 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Devore Susan D.

    4 - Solventum Corp (0001964738) (Issuer)

    5/18/26 5:38:52 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Solventum Appoints Heather Knight as Chief Commercial Officer

    ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale

    10/21/25 5:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum Reports First Quarter 2026 Financial Results

    Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating

    5/5/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026

    ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Tuesday, May 5, 2026Time:3:30 p.m. CDT / 4:30 p.m. EDTLocation:https://investors.solventum.com U.S. dial-in+1 (800) 715-9871International dial-in: +1 (646) 307-1963Conference ID:63

    4/14/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

    Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

    2/26/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care